3 May 2010

Ellex To Present New Clinical Results For Ellex 2Rt At Arvo 2010

Adelaide, Australia, 3 May 2010: Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, announced today that initial clinical results of two new studies for Ellex Retina Regeneration Therapy (Ellex 2RT™) will be presented at the Association for Research in Vision and Ophthalmology’s (ARVO) 2010 Annual Meeting, which takes place 2-6 May in Fort Lauderdale.

The studies, which form part of the Ellex 2RT™ Research Program, investigate the efficacy of Ellex 2RT™ for the treatment of Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) respectively – two of the leading causes of blindness in the developed world.

According to Simon Luscombe, Ellex CEO, the clinical results of these new studies mark an important milestone in the advancement of the science and technology of Ellex 2RT™.

“Each year ARVO brings together the world’s leading eye and vision researchers, and we are pleased to be in a position to update the ARVO scientific community on our continued progress with the Ellex 2RT Research Program”, commented Mr. Luscombe.


Ellex 2RT for Early AMD

The “2RT for Early AMD” study is being undertaken in partnership with the Centre for Eye Research Australia (CERA) and the Royal Victorian Eye and Ear Hospital. Preeminent AMD researcher and Head of Macular Research at CERA, Professor Robyn Guymer, MB, BS, PhD, FRANZCO, is leading the prospective, comparative study to investigate the efficacy of Ellex 2RT™ for the treatment of early AMD.

“Currently, when a patient is diagnosed with early AMD, they’re told that nothing can be done until the disease reaches its late stages, by which time some patients have suffered irreversible vision loss,” Professor Guymer said.

“With Ellex 2RT™, we hope to halt, or partially reverse, the progression of AMD before it threatens a patient’s sight.”

Professor Guymer will present the initial 6-month study results at the upcoming ARVO 2010 Annual Meeting: Poster Session 121 (AMD II), Sunday 2 May (US Eastern Time).

Ellex 2RT for Diabetic Retinopathy

The “2RT for Proliferative Diabetic Retinopathy” study is being conducted at several study sites in Australia under principal investigator Associate Professor Robert Casson, MB, BS (Hons), DPhil, FRANZCO. This clinical prospective, double blind comparative investigation aims to compare the efficacy of Ellex 2RT™ with retinal laser photocoagulation for the treatment of DR.

Associate Professor Casson will present the completed 6-month study results at the upcoming ARVO 2010 Annual Meeting: Paper Session 542 (Diabetic Retinopathy IV), Thursday 6 May (US Eastern Time).


Ellex Medical Lasers Limited (ASX: ELX) designs, manufactures and markets a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound systems for ophthalmology, initiating the expansion of our product line beyond lasers. The Ellex name has long been synonymous with excellence in technology, in quality, and in customer care. Ellex maintains the highest quality standards through product development and manufacturing, and strives to provide unmatched levels of clinical expertise and support to our customers. All of these efforts have combined to produce one of the highest levels of customer satisfaction in the ophthalmic industry.


Ellex 2RT™ is a non-damaging laser treatment that stimulates a therapeutic response to regenerate retinal tissue that has been compromised by disease or age. This breakthrough therapy is aimed at treating a range of degenerative diseases that ultimately result in blindness, including AMD. Early clinical trials have been conducted at St. Thomas’ Hospital in London, with further clinical trials currently underway in Australia to validate the efficacy of Ellex 2RT™ for a number of clinical indications.

For additional information about Ellex 2RT™, please visit www.ellex.com/2RT